Generic Name and Formulations:
Erythromycin (as base) 250mg; e-c pellets in caps.
Mayne Pharma US
Indications for ERYC:
Treatment of susceptible infections including upper and lower respiratory, skin and skin structure, genitourinary, Legionnaires' disease, pertussis, listeriosis. Prophylaxis for rheumatic fever attacks in penicillin-allergic patients.
Give 1hr before meals. Usual dose: 250mg every 6hrs or 500mg every 12hrs; max 4g/day (1g/day for twice daily dosing). Legionnaires: 1–4g/day in divided doses. Prophylaxis: 250mg twice daily. See full labeling.
Give 1hr before meals. Usual dose: 30–50mg/kg/day in divided doses; may double dose in severe infections. See full labeling.
Concomitant terfenadine, astemizole, cisapride, pimozide, ergotamine, dihydroergotamine, statins (eg, lovastatin, simvastatin).
Avoid in proarrhythmic conditions (eg, uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia); risk of QT prolongation. Myasthenia gravis. Hepatic impairment. Elderly. Infants: risk of infantile hypertrophic pyloric stenosis; monitor for vomiting or irritability with feeding. Pregnancy (Cat.B). Nursing mothers.
See Contraindications. May potentiate theophylline (reduce dose of theophylline), digoxin, oral anticoagulants, hexobarbital, phenytoin, valproate. May potentiate CYP3A substrates (eg, triazolam, midazolam, statins [rhabdomyolysis], sildenafil [reduce dose of sildenafil], colchicine [reduce starting dose of colchicine, max dose should be lowered; monitor], verapamil, amlodipine, diltiazem, carbamazepine, cyclosporine, tacrolimus, alfentanil, disopyramide, bromocriptine, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine); consider dose adjustments and monitor. May be antagonized by theophylline. Hypotension, bradyarrhythmias, lactic acidosis with verapamil. QT prolongation with concomitant Class 1A (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmics; avoid. May interfere with fluorometric detection of urinary catecholamines.
GI upset, abdominal pain, anorexia, hepatic dysfunction; QT prolongation, C. difficile-associated diarrhea, superinfection (discontinue if occurs).
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Encorafenib, Binimetinib Combination Receives FDA Approval for Mutation-Positive Melanoma
- Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Patient Interest in Melanoma Genetic Risk Testing is Fairly High
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Bleeding Disorder Treatments: Hemophilia A
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|